{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T19:37:09Z","timestamp":1778701029466,"version":"3.51.4"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T00:00:00Z","timestamp":1741737600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Human immunodeficiency virus type 2 (HIV-2) is an attenuated retroviral infection characterized by specific natural susceptibility to antiretroviral drugs and acquired resistance profiles. Based on the latest knowledge of phenotypic data and clinical follow-up, HIV-2 resistance interpretation rules have been updated and implemented in a freely available resistance analysis tool.<\/jats:p>","DOI":"10.1093\/cid\/ciaf110","type":"journal-article","created":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T07:32:01Z","timestamp":1741764721000},"page":"539-542","source":"Crossref","is-referenced-by-count":3,"title":["HIV-2 EU\u2014Supporting Standardized HIV-2 Drug Resistance Interpretation: An Update"],"prefix":"10.1093","volume":"81","author":[{"given":"Charlotte","family":"Charpentier","sequence":"first","affiliation":[{"name":"Universit\u00e9 Paris Cit\u00e9, INSERM, UMR 1137, IAME , Paris ,","place":["France"]},{"name":"Service de Virologie, AP-HP, H\u00f4pital Bichat-Claude Bernard , Paris ,","place":["France"]}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9143-4259","authenticated-orcid":false,"given":"Dirk","family":"Berzow","sequence":"additional","affiliation":[{"name":"Praxis for Infectiology , Hamburg ,","place":["Germany"]},{"name":"Deutsche Arbeitsgemeinschaft niedergelassener \u00c4rzte in der Versorgung HIV-Infizierter (dagn\u00e4) , Berlin ,","place":["Germany"]}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9017-4941","authenticated-orcid":false,"given":"Quentin","family":"Le Hingrat","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Cit\u00e9, INSERM, UMR 1137, IAME , Paris ,","place":["France"]},{"name":"Service de Virologie, AP-HP, H\u00f4pital Bichat-Claude Bernard , Paris ,","place":["France"]}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2640-2548","authenticated-orcid":false,"given":"Rolf","family":"Kaiser","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and University Hospital of Cologne, Institute of Virology, University of Cologne , Cologne ,","place":["Germany"]},{"name":"Deutsche AIDS-Gesellschaft e.V. (DAIG) , Essen ,","place":["Germany"]}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3271-8255","authenticated-orcid":false,"given":"Perpetua","family":"Gomes","sequence":"additional","affiliation":[{"name":"Molecular Biology Laboratory, SPC, Unidade Local de Sa\u00fade Lisboa Ocidental, Egas Moniz Hospital , Lisboa ,","place":["Portugal"]},{"name":"Egas Moniz Center for Interdisciplinary Research (CiiEM), Egas Moniz School of Health & Science , Almada ,","place":["Portugal"]}]},{"given":"Ana Claudia","family":"Miranda","sequence":"additional","affiliation":[{"name":"Infecciology, Hospital de Egas Moniz, Unidade Local de Sa\u00fade Lisboa Ocidental , Lisbon ,","place":["Portugal"]}]},{"given":"Florence","family":"Damond","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Cit\u00e9, INSERM, UMR 1137, IAME , Paris ,","place":["France"]},{"name":"Service de Virologie, AP-HP, H\u00f4pital Bichat-Claude Bernard , Paris ,","place":["France"]}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2914-959X","authenticated-orcid":false,"given":"Jade","family":"Ghosn","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Cit\u00e9, INSERM, UMR 1137, IAME , Paris ,","place":["France"]},{"name":"Service de Maladies Infectieuses et Tropicales, AP-HP, H\u00f4pital Bichat-Claude Bernard , Paris ,","place":["France"]}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7625-8230","authenticated-orcid":false,"given":"Jeroen J A","family":"van Kampen","sequence":"additional","affiliation":[{"name":"Department of Viroscience, Erasmus University Medical Center , Rotterdam ,","place":["The Netherlands"]}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1626-4855","authenticated-orcid":false,"given":"Bj\u00f6rn-Erik Ole","family":"Jensen","sequence":"additional","affiliation":[{"name":"Deutsche AIDS-Gesellschaft e.V. (DAIG) , Essen ,","place":["Germany"]},{"name":"Department of Gastroenterology, Hepatology, and Infectious Diseases, Medical Faculty and University Hospital D\u00fcsseldorf, Heinrich Heine University , D\u00fcsseldorf ,","place":["Germany"]}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1208-8647","authenticated-orcid":false,"given":"Michael","family":"B\u00f6hm","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and University Hospital of Cologne, Institute of Virology, University of Cologne , Cologne ,","place":["Germany"]},{"name":"Deutsche AIDS-Gesellschaft e.V. (DAIG) , Essen ,","place":["Germany"]}]},{"given":"Annemarie M J","family":"Wensing","sequence":"additional","affiliation":[{"name":"Department of Global Health and Bio-ethics, Julius Center for Primary Care and Health Sciences, University Medical Center Utrecht , Utrecht ,","place":["The Netherlands"]}]},{"given":"Diane","family":"Descamps","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Cit\u00e9, INSERM, UMR 1137, IAME , Paris ,","place":["France"]},{"name":"Service de Virologie, AP-HP, H\u00f4pital Bichat-Claude Bernard , Paris ,","place":["France"]}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2511-9553","authenticated-orcid":false,"given":"Martin","family":"Obermeier","sequence":"additional","affiliation":[{"name":"Deutsche Arbeitsgemeinschaft niedergelassener \u00c4rzte in der Versorgung HIV-Infizierter (dagn\u00e4) , Berlin ,","place":["Germany"]},{"name":"MVZ Medizinisches Infektiologiezentrum Berlin , Berlin ,","place":["Germany"]}]}],"member":"286","published-online":{"date-parts":[[2025,3,12]]},"reference":[{"key":"2025100602573081500_ciaf110-B1","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1093\/cid\/civ572","article-title":"HIV-2EU: supporting standardized HIV-2 drug resistance interpretation in Europe: an update","volume":"61","author":"Charpentier","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2025100602573081500_ciaf110-B2","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1093\/cid\/ciaa275","article-title":"Human immunodeficiency virus-2 (HIV-2): a summary of the present standard of care and treatment options for individuals living with HIV-2 in Western Europe","volume":"72","author":"Berzow","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2025100602573081500_ciaf110-B3","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1093\/cid\/cit104","article-title":"HIV-2EU: supporting standardized HIV-2 drug resistance interpretation in Europe","volume":"56","author":"Charpentier","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2025100602573081500_ciaf110-B4","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1128\/AAC.05313-11","article-title":"In vitro phenotypic susceptibility of HIV-2 clinical isolates to CCR5 inhibitors","volume":"56","author":"Visseaux","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2025100602573081500_ciaf110-B5","doi-asserted-by":"crossref","first-page":"3498","DOI":"10.1128\/AAC.00426-12","article-title":"In vitro antiviral characteristics of HIV-1 attachment inhibitor BMS-626529, the active component of the prodrug BMS-663068","volume":"56","author":"Nowicka-Sans","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2025100602573081500_ciaf110-B6","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1177\/135965350400900115","article-title":"Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis","volume":"9","author":"Witvrouw","year":"2004","journal-title":"Antivir Ther"},{"key":"2025100602573081500_ciaf110-B7","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1097\/QAD.0000000000003218","article-title":"Ibalizumab shows in-vitro activity against group A and group B HIV-2 clinical isolates","volume":"36","author":"Le Hingrat","year":"2022","journal-title":"AIDS"},{"key":"2025100602573081500_ciaf110-B8","doi-asserted-by":"crossref","first-page":"e00744-17","DOI":"10.1128\/AAC.00744-17","article-title":"MK-8591 (4\u2032-ethynyl-2-fluoro-2\u2032-deoxyadenosine) exhibits potent activity against HIV-2 isolates and drug-resistant HIV-2 mutants in culture","volume":"61","author":"Wu","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2025100602573081500_ciaf110-B9","doi-asserted-by":"crossref","first-page":"e0013322","DOI":"10.1128\/aac.00133-22","article-title":"Islatravir has a high barrier to resistance and exhibits a differentiated resistance profile from approved nucleoside reverse transcriptase inhibitors (NRTIs)","volume":"66","author":"Diamond","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"2025100602573081500_ciaf110-B10","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1016\/j.biocel.2008.04.007","article-title":"2\u2032-deoxy-4\u2032-C-ethynyl-2-halo-adenosines active against drug-resistant human immunodeficiency virus type 1 variants","volume":"40","author":"Kawamoto","year":"2008","journal-title":"Int J Biochem Cell Biol"},{"key":"2025100602573081500_ciaf110-B11","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1128\/AAC.01284-07","article-title":"In vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors","volume":"52","author":"Desbois","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"2025100602573081500_ciaf110-B12","doi-asserted-by":"crossref","first-page":"e00014-19","DOI":"10.1128\/AAC.00014-19","article-title":"Comparison of the antiviral activity of bictegravir against HIV-1 and HIV-2 isolates and integrase inhibitor-resistant HIV-2 mutants","volume":"63","author":"Smith","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2025100602573081500_ciaf110-B13","doi-asserted-by":"crossref","first-page":"e01299-18","DOI":"10.1128\/AAC.01299-18","article-title":"In vitro antiviral activity of cabotegravir against HIV-2","volume":"62","author":"Smith","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2025100602573081500_ciaf110-B14","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1093\/jac\/dkn335","article-title":"HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro","volume":"62","author":"Roquebert","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"2025100602573081500_ciaf110-B15","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1097\/QAD.0b013e32833f9e36","article-title":"In-vitro phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitor S\/GSK1349572","volume":"24","author":"Charpentier","year":"2010","journal-title":"AIDS"},{"key":"2025100602573081500_ciaf110-B16","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s007050170143","article-title":"A single amino acid change at Leu-188 in the reverse transcriptase of HIV-2 and SIV renders them sensitive to non-nucleoside reverse transcriptase inhibitors","volume":"146","author":"Isaka","year":"2001","journal-title":"Arch Virol"},{"key":"2025100602573081500_ciaf110-B17","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1128\/AAC.00986-09","article-title":"TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1","volume":"54","author":"Azijn","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"2025100602573081500_ciaf110-B18","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1093\/cid\/ciy940","article-title":"A new mechanism of resistance of human immunodeficiency virus type 2 to integrase inhibitors: a 5-amino-acid insertion in the integrase C-terminal domain","volume":"69","author":"Le Hingrat","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2025100602573081500_ciaf110-B19","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1093\/jac\/dkab387","article-title":"In vitro analysis of the replicative capacity and phenotypic susceptibility to integrase inhibitors of HIV-2 mutants with integrase insertions","volume":"77","author":"Le Hingrat","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"2025100602573081500_ciaf110-B20","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1093\/infdis\/jiac037","article-title":"Spectrum of activity of raltegravir and dolutegravir against novel treatment-associated mutations in HIV-2 integrase: a phenotypic analysis using an expanded panel of site-directed mutants","volume":"226","author":"Smith","year":"2022","journal-title":"J Infect Dis"},{"key":"2025100602573081500_ciaf110-B21","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1093\/infdis\/jiaa026","article-title":"Expanded spectrum of antiretroviral-selected mutations in human immunodeficiency virus type 2","volume":"221","author":"Tzou","year":"2020","journal-title":"J Infect Dis"},{"key":"2025100602573081500_ciaf110-B22","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1093\/jac\/dkr389","article-title":"The HIV-1 integrase G118R mutation confers raltegravir resistance to the CRF02_AG HIV-1 subtype","volume":"66","author":"Malet","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"2025100602573081500_ciaf110-B23","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.1128\/JVI.06591-11","article-title":"Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir","volume":"86","author":"Quashie","year":"2012","journal-title":"J Virol"},{"key":"2025100602573081500_ciaf110-B24","doi-asserted-by":"crossref","first-page":"ofae705","DOI":"10.1093\/ofid\/ofae705","article-title":"Novel dolutegravir and lenacapavir resistance patterns in human immunodeficiency virus type 2 infection: a case report","volume":"12","author":"van Kampen","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"2025100602573081500_ciaf110-B25","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1093\/jac\/dkx090","article-title":"Drug resistance mutations in HIV-2 patients failing raltegravir and influence on dolutegravir response","volume":"72","author":"Requena","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2025100602573081500_ciaf110-B26","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1093\/infdis\/jiad562","article-title":"Antiviral activity of lenacapavir against human immunodeficiency virus type 2 (HIV-2) isolates and drug-resistant HIV-2 mutants","volume":"229","author":"Smith","year":"2024","journal-title":"J Infect Dis"},{"key":"2025100602573081500_ciaf110-B27","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1093\/cid\/ciae650","article-title":"Rapid selection of HIV-2 capsid mutations in salvage therapy with lenacapavir-containing regimen","volume":"81","author":"Montrouge","year":"2025","journal-title":"Clin Infect Dis"},{"key":"2025100602573081500_ciaf110-B28","volume-title":"Program and abstracts of the 19th European AIDS conference (EACS 2023) (Varsaw)","author":"Degen"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciaf110\/62385142\/ciaf110.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/81\/3\/539\/62385142\/ciaf110.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/81\/3\/539\/62385142\/ciaf110.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T06:57:43Z","timestamp":1759733863000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/81\/3\/539\/8071572"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,12]]},"references-count":28,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3,12]]},"published-print":{"date-parts":[[2025,10,6]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciaf110","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9,15]]},"published":{"date-parts":[[2025,3,12]]}}}